RMC No. 100-2024 publishes FDA updates to VAT-exempt medicines and confirms exemption applies from the FDA publication date of the updated list.
Businesses selling, purchasing, prescribing, distributing, or accounting for covered medicines must immediately check whether their products are included in the updated FDA-endorsed list of VAT-exempt products, because VAT exemption under RMC No. 100-2024 depends on the publication by the Food and Drug Administration of the updated list. The practical consequence is direct: covered medicines for cancer, diabetes, hypertension, kidney diseases, mental illness, and tuberculosis may be treated as VAT-exempt only in accordance with the published FDA update endorsed to the BIR.
What RMC No. 100-2024 Changes
RMC No. 100-2024 publishes the full text of the August 7, 2024 letter from the Food and Drug Administration of the Department of Health endorsing updates to the list of VAT-exempt products under Republic Act No. 10963, also known as the TRAIN Law, and Republic Act No. 11534, also known as the CREATE Act. The circular is addressed to all internal revenue officers and others concerned, and it serves as the BIRโs formal publication of the FDA endorsement for certain medicines to be included in the published List of VAT-Exempt Medicines.
The specific categories identified in RMC No. 100-2024 are medicines for cancer, diabetes, hypertension, kidney diseases, mental illness, and tuberculosis. For businesses in the pharmaceutical and healthcare supply chain, this is not merely a tax technicality. It affects invoice treatment, price computation, VAT reporting, input and output VAT reconciliation, accounting system setup, and the documentation that may be reviewed during a BIR audit.
The most important rule in the circular is that the effectivity of the VAT exemption is tied to publication by the FDA of the updates to the list. RMC No. 100-2024 expressly reiterates the clarification under Q&A No. 1 of RMC No. 99-2021: the effectivity of the VAT exemption of covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the said list.
Who Is Most Affected by the Updated VAT-Exempt Medicine List
The businesses most directly affected are pharmaceutical companies, medicine importers, drug distributors, wholesalers, pharmacies, hospitals, clinics, healthcare institutions, and other entities selling or procuring covered medicines. The update is especially relevant to businesses dealing with medicines for cancer, diabetes, hypertension, kidney disease, mental illness, and tuberculosis, because these categories are expressly mentioned in the circular.
Corporate accountants and tax managers of hospitals, pharmacies, and drug distributors should also review their VAT treatment immediately. A product that is already included in the FDA-published list may require VAT-exempt treatment from the applicable publication date. Conversely, a medicine that is not included in the FDA-published list should not be treated as exempt merely because it appears to fall within a broad disease category. The controlling point is inclusion in the published list endorsed by the FDA and recognized through the BIR issuance.
Procurement departments and CFOs should also pay attention to this update. VAT treatment affects landed cost, supplier pricing, billing to patients or customers, and tax reporting. For businesses operating with large medicine inventories, the timing of the FDA publication date may affect the treatment of sales made before and after the relevant publication.
Key Compliance Requirement: Check the FDA Publication Date
RMC No. 100-2024 does not create a separate application process in the circular itself. Instead, it emphasizes the publication of the FDA-endorsed updates and reiterates the existing rule on effectivity. The compliance question for taxpayers is therefore practical: was the medicine included in the FDA-published update, and from what publication date should the VAT exemption be applied?
The relevant FDA endorsement letter is dated August 7, 2024. The circular itself bears Revenue Memorandum Circular No. 100-2024 and was released under the authority of the Commissioner of Internal Revenue. The document reflects BIR receipt and release markings in September 2024. For compliance purposes, taxpayers should treat the official FDA publication date of the update as the operative date for VAT exemption, consistent with the rule repeated in the circular.
Businesses should not apply the VAT exemption based only on internal assumptions, supplier representations, or product classification descriptions. The safer tax position is to maintain documentary proof that the specific medicine appears in the FDA-published list of VAT-exempt products and to align invoices, receipts, accounting entries, and VAT returns with the applicable publication date.
What Accountants Should Do for Sales, Purchases, and Invoices
For sales of covered medicines, the accounting team should determine whether each product SKU is included in the FDA-published update and whether the sale occurred on or after the effective publication date. If both requirements are satisfied, the sale should be treated consistently as VAT-exempt in the taxpayerโs invoicing and tax reporting system.
For purchases of covered medicines, buyers should review supplier invoices and confirm whether VAT was properly excluded for products covered by the updated list. If suppliers continue to charge VAT on products that are already covered by the FDA-published list from the proper date, businesses may need to request corrected billing documents or obtain clarification from the supplier. This is particularly important for hospitals, pharmacies, and healthcare institutions with high-volume purchases of chronic disease medicines and specialty drugs.
For inventory already in stock, businesses should avoid a blanket reclassification without checking the timing and product-level coverage. A medicine category such as diabetes, cancer, or hypertension is not enough by itself. The exact product must be validated against the published list. This is the type of detail BIR examiners may look for if a taxpayer reports VAT-exempt sales or adjusts VAT treatment after the issuance.
Deadlines and Effectivity Under RMC No. 100-2024
The central date stated in the circular is August 7, 2024, the date of the FDA letter endorsing updates to the list of VAT-exempt products. However, the operative effectivity rule is not simply the date of the FDA letter. RMC No. 100-2024 reiterates that, under Q&A No. 1 of RMC No. 99-2021, the VAT exemption of covered medicines and medical devices under the CREATE Act becomes effective on the date of publication by the FDA of the updates to the list.
This means CFOs and tax teams should verify the FDA publication date for the updated list and use that date as the reference point for tax treatment. Sales before the applicable publication date should not be retroactively treated as exempt unless a separate rule or issuance clearly allows it. Sales on or after the FDA publication date should be reviewed for proper VAT-exempt classification if the product is included in the published update.
Penalties for Non-Compliance
RMC No. 100-2024 does not provide a new special penalty table, surcharge, interest rate, or administrative fine for non-compliance. The risk for businesses is therefore not a new penalty created by this circular, but the ordinary tax exposure that may arise from incorrect VAT treatment, improper invoicing, unsupported VAT-exempt sales, or inconsistent VAT return reporting.
For sellers, the main risk is treating products as VAT-exempt without sufficient basis in the FDA-published list. For buyers, the risk is accepting invoices or accounting treatment that may later need correction. For large companies, hospitals, and distributors, repeated mistakes across numerous SKUs can create material exposure in a BIR audit, particularly where accounting systems are not updated promptly after the FDA publication.
Practical Steps for Businesses Now
First, identify all products in your portfolio or procurement list that fall under medicines for cancer, diabetes, hypertension, kidney diseases, mental illness, and tuberculosis. Second, check each product against the FDA-published list of VAT-exempt medicines covered by the August 7, 2024 endorsement published through RMC No. 100-2024. Third, determine the applicable FDA publication date and apply the VAT-exempt treatment only from that date, consistent with RMC No. 99-2021 as reiterated in the circular.
Fourth, update your invoicing, point-of-sale, ERP, and accounting systems so that product-level VAT treatment is accurate. Fifth, preserve documentation showing the basis for the VAT exemption, including the applicable BIR issuance reference, FDA publication basis, product inclusion, and date of effectivity. Sixth, review supplier and customer contracts where pricing is VAT-sensitive, especially if the contract assumes VAT-inclusive or VAT-exclusive billing.
For search and compliance tracking, tax teams should use the exact phrases likely to appear in internal working papers and BIR audit files: RMC No. 100-2024 VAT-exempt medicines, FDA VAT exemption list Philippines, CREATE Act VAT exemption medicines, TRAIN Law VAT-exempt drugs, and VAT-exempt medicines cancer diabetes hypertension kidney disease mental illness tuberculosis.
How Ablola, Saribong & Gueco Can Help
RMC No. 100-2024 is important because it affects both tax compliance and commercial pricing for healthcare and pharmaceutical businesses. The difficult part is not merely knowing that a medicine category may be VAT-exempt. The difficult part is proving product-level inclusion, applying the correct effectivity date, issuing compliant invoices, and defending the treatment if questioned by the BIR.
Ablola, Saribong & Gueco assists businesses, CFOs, accountants, healthcare institutions, pharmacies, distributors, and corporate legal teams in reviewing BIR issuances, validating VAT treatment, preparing tax compliance documentation, and managing BIR audit risk. For assistance with RMC No. 100-2024, VAT-exempt medicines, FDA list validation, or broader BIR compliance, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.